SFEBES2014 Poster Presentations Bone (30 abstracts)
1School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, Centre for Endocrinology, Diabetes, and Metabolism, University of Birmingham, Edgbaston, Birmingham B15 2TT, West Midlands, UK; 2Department of Medicine Old QEH and 2nd Floor Wolfson Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Medical Centre, Queen Elizabeth Hospital, Birmingham B15 2TH, West Midlands, UK.
Gauchers disease is an inherited disorder caused by loss or reduced activity of the lysosomal enzyme glucocerebrosidase (GBA). Nearly 80% of patients with Gauchers disease develop abnormal bone remodelling with severe consequences, including bone crises, osteonecrosis and osteoporosis related fractures. Although enzyme replacement therapy is effective at alleviating most manifestations of the disease, only modest improvements in bone health can be achieved. The reason for this apparent bone resistance is unclear but may reflect abnormal osteoclast function. To address this problem, we developed an in vitro model of osteoclast bone resorption, in which we differentiated the mouse cell line RAW264.7, into functional osteoclasts using RANKL. Multinucleated tartrate resistant alkaline phosphatase (TRAP) positive cells were apparent after 7 days of culture on uncoated tissue culture plastic.
Osteoclasts were differentiated on inorganic calcium phosphate coated plates designed to mimic the in vivo bone environment. Cultures were maintained for 14 days and the Gauchers defect was modelled by culturing cells in the presence of conduritol-β-epoxide (CBE), a potent, irreversible inhibitor of mammalian GBA. After the culture period, cells were removed and the number of resorption pits counted. We observed that the number of osteoclasts and resorption pits was increased by twenty percent following culture in the presence of 50 μM CBE and this effectively doubled at 100 μM.
Our novel in vitro model of Gauchers osteoclasts mirrors observations made in studies using osteoclasts derived from the peripheral blood of patients with Gauchers disease. This system may provide a useful tool for understanding the mechanisms of increased bone turnover in Gauchers disease and in particular the intracellular consequences of perturbed GBA activity within the osteoclast. This may provide insights for the development of alternative or complementary therapies to prevent the aberrant bone turnover associated with this rare disease.